Panel discusses long-awaited end to the COVID-19 pandemic thejustice.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thejustice.org Daily Mail and Mail on Sunday newspapers.
E-Mail
Amsterdam, April 6, 2021 - The rarity of spinal muscular atrophy (SMA) means that promising new treatments may be tested in only a limited spectrum of patients before approval. Investigators evaluated a newly approved drug, onasemnogene abeparvovec, in a broader spectrum of patients in order to obtain expanded data on its side effects profile. They report in the
Journal of Neuromuscular Diseases that the drug is associated with an immune response against the adeno-associated viral vector and needs careful monitoring, but showed no long-term adverse effects.
In recent years, the availability of a growing number of drug treatments has significantly changed the course of the SMA. One of these is onasemnogene abeparvovec (Zolgensma®), an adeno-associated viral (AAV9) vector-based gene therapy that introduces a functional copy of the
Researchers evaluate new drug for spinal muscular atrophy in a broader spectrum of patients
The rarity of spinal muscular atrophy (SMA) means that promising new treatments may be tested in only a limited spectrum of patients before approval. Investigators evaluated a newly approved drug, onasemnogene abeparvovec, in a broader spectrum of patients in order to obtain expanded data on its side effects profile. They report in the
Journal of Neuromuscular Diseases that the drug is associated with an immune response against the adeno-associated viral vector and needs careful monitoring, but showed no long-term adverse effects.
In recent years, the availability of a growing number of drug treatments has significantly changed the course of the SMA. One of these is onasemnogene abeparvovec (Zolgensma®), an adeno-associated viral (AAV9) vector-based gene therapy that introduces a functional copy of the
Nerve cell activity shows how confident individuals are
A total of twelve men and women took part in their experiment.
By ANI| Posted by Sakina Fatima | Published: 5th April 2021 6:17 pm IST Representative Image
Washington: A recent study conducted by researchers at the University of Bonn suggests that the activity of individual nerve cells in the brain tells us how confident we are in our decisions.
The result is unexpected – the researchers were actually on the trail of a completely different evaluation mechanism. The results are published in the journal Current Biology.
Every day humans have to make decisions. Researchers at the University Hospital Bonn have now identified nerve cells in the brain whose activity indicates the confidence in decisions.
(1)
Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo Cerebral Protection System. The ProtEmbo System is an intra-aortic filter device that deflects embolic material away from the brain during transcatheter aortic valve replacement (TAVR). The device is a low profile system which is delivered through the left radial artery, an ideal access site enabling physicians to avoid interference with TAVR equipment, typically delivered through the left femoral artery.